Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Recent studies show an important role for non-neutralizing anti-spike antibodies, including
monoclonal antibodies (mAbs), in robustly protecting against SARS-CoV-2 infection. These …

A key barrier to the development of vaccines that induce broadly neutralizing antibodies
(bnAbs) against human immunodeficiency virus (HIV) and other viruses of high antigenic …

Abstract Ever-evolving SARS-CoV-2 variants of concern (VOCs) have diminished the
effectiveness of therapeutic antibodies and vaccines. Develo** a coronavirus vaccine that …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein binds the
receptor angiotensin converting enzyme 2 (ACE2) and drives virus-host membrane fusion …

Pan-betacoronavirus neutralizing antibodies may hold the key to develo** broadly
protective vaccines against novel pandemic coronaviruses and to more effectively respond …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution has resulted in
viral escape from clinically authorized monoclonal antibodies (mAbs), creating a need for …

Since the onset of the coronavirus disease 2019 (COVID-19), numerous neutralizing
antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Since the emergence of the Omicron variants at the end of 2021, they quickly became the
dominant variants globally. The Omicron variants may be more easily transmitted compared …

Antigenic drift of SARS-CoV-2 is typically defined by mutations in the N-terminal domain and
receptor binding domain of spike protein. In contrast, whether antigenic drift occurs in the S2 …